Analysts Set Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) PT at $54.20

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) have been assigned an average rating of "Buy" from the seven analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $54.20.

A number of brokerages have issued reports on TARS. The Goldman Sachs Group boosted their price objective on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a "neutral" rating in a research report on Friday, November 15th. William Blair raised shares of Tarsus Pharmaceuticals to a "strong-buy" rating in a research report on Friday, August 30th. Finally, Oppenheimer boosted their price objective on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an "outperform" rating in a research report on Thursday, November 14th.

Tarsus Pharmaceuticals Stock Up 3.2 %

Shares of NASDAQ TARS traded up $1.61 during mid-day trading on Friday, hitting $52.45. The stock had a trading volume of 290,714 shares, compared to its average volume of 723,093. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals has a 1 year low of $15.60 and a 1 year high of $52.99. The business has a 50 day moving average price of $40.37 and a two-hundred day moving average price of $33.19.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Quest Partners LLC bought a new position in Tarsus Pharmaceuticals in the 2nd quarter worth about $61,000. Canada Pension Plan Investment Board bought a new position in Tarsus Pharmaceuticals during the 2nd quarter valued at about $114,000. FMR LLC lifted its stake in Tarsus Pharmaceuticals by 236.6% during the 3rd quarter. FMR LLC now owns 5,032 shares of the company's stock valued at $166,000 after acquiring an additional 3,537 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Tarsus Pharmaceuticals by 33.4% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company's stock valued at $166,000 after acquiring an additional 1,530 shares during the period. Finally, SG Americas Securities LLC lifted its stake in Tarsus Pharmaceuticals by 87.5% during the 3rd quarter. SG Americas Securities LLC now owns 7,242 shares of the company's stock valued at $238,000 after acquiring an additional 3,379 shares during the period. Institutional investors own 90.01% of the company's stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.